Skip to main content

Remote Job Finders (RJF)

Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Scroll to top